Aaron Balog

Bristol-Myers Squibb (Sweden) — Sweden

Medicine · Health Sciences

28h-index3.2kcitations104works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(26), Synthetic Organic Chemistry Methods(24), Prostate Cancer Treatment and Research(22), Estrogen and related hormone effects(20), Tryptophan and brain disorders(17)

Publications104 total

Abstract ND05: The discovery of BMS-986449, a highly potent and selective degrader of the transcription factors Helios (IKZF2) and Eos (IKZF4) for the treatment of solid tumors
Cancer Research·2025· 1 cited
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1
Bioorganic & Medicinal Chemistry Letters·2023· 5 citedOpen Access
Supplementary Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
2023Open Access
Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
2023Open Access
Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
2023Open Access
Supplementary Table 2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Table 2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Data from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Table 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Figure 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Table 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Figure and Table Legends 1-2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Data from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Figure and Table Legends 1-2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Supplementary Figure 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
2023Open Access
Synthesis and Biological Evaluation of Biaryl Alkyl Ethers as Inhibitors of IDO1
SSRN Electronic Journal·2023· 1 citedOpen Access
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer
Bioorganic & Medicinal Chemistry Letters·2022· 7 citedOpen Access
Quantification of Linrodostat and its metabolites: Overcoming bioanalytical challenges in support of a discovery Indoleamine 2,3 dioxygenase program
Journal of Chromatography B·2022· 2 cited
Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; <i>N</i>-((<i>R</i>)-1-((<i>cis</i>)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide
Organic Process Research & Development·2021· 5 cited
page 1 of 6Next →

Frequent Co-authors

Samuel J. Danishefsky(18), Gregory D. Vite(13), Weifang Shan(12), John T. Hunt(11), Ting‐Chao Chou(11), Marco M. Gottardis(10), Peter Bertinato(9), Dai‐Shi Su(9), Ricardo M. Attar(9), Cheryl A. Rizzo(9), Dong‐Fang Meng(8), Mark Salvati(8), Erik J. Sorensen(7), Christina R. Harris(7), Mary T. Obermeier(7), Derrick Maley(6), Lifeng He(6), Susan Band Horwitz(6), Dennis P. Curran(6), Jieping Geng(6)